Carregant...
Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic Leukemia in the United States: A large population-based study
BACKGROUND: Despite approval of azacitidine in 2004 and decitabine in 2006 in the US for chronic myelomonocytic leukemia (CMML), overall survival (OS) benefit with hypomethylating agent (HMA) therapy is unclear. METHODS: We selected older adults (age ≥66 years) diagnosed with CMML during 2001–2011 f...
Guardat en:
| Publicat a: | Cancer |
|---|---|
| Autors principals: | , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6540984/ https://ncbi.nlm.nih.gov/pubmed/28621841 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30814 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|